Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene |
| Completed | 2b | 129 | US, Canada, Europe, RoW | JX-594 recombinant vaccina GM-CSF, Best Supportive Care | Jennerex Biotherapeutics | Hepatocellular Carcinoma, Liver Cancer, HCC | 12/11 | 12/11 | | |
|
NCT01329809: Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors |
|
|
| Terminated | 2a | 2 | Canada | Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594), JX-594 | Jennerex Biotherapeutics | Colorectal Carcinoma | 01/12 | 03/13 | | |
NCT00554372: A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma |
|
|
| Completed | 2 | 30 | US, Canada, RoW | JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF) | Jennerex Biotherapeutics | Carcinoma, Hepatocellular | 12/11 | 02/13 | | |
NCT01171651: A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma |
|
|
| Completed | 2 | 25 | RoW | JX-594 followed by sorafenib | Jennerex Biotherapeutics | Carcinoma, Hepatocellular | 02/13 | 12/15 | | |
NCT02017678: Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin |
|
|
| Withdrawn | 2 | 0 | Canada | JX-594, vaccinia virus | Andrea McCart, Ontario Institute for Cancer Research | Ovarian Cancer | 01/15 | 06/15 | | |
NCT00429312: A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma |
|
|
| Completed | 1/2 | 10 | US | JX-594, JX594 | Jennerex Biotherapeutics | Melanoma | 02/08 | 12/09 | | |